查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1344484

脊髓性肌肉萎缩症 (SMA) 治疗市场：按类型、给药途径和最终用户分类：2023-2032 年全球机会分析和产业预测

Spinal Muscular Atrophy Treatment Market By Type (Type 1, Type 2, Others), By Route of Administration (Oral, Parenteral), By End User (Hospitals, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 239 Pages | 商品交期: 2-3个工作天内

价格

根据联合市场研究公司发布的一份新报告，2022 年脊髓性肌肉萎缩症(SMA) 治疗市场价值为43 亿美元，2023 年至2032 年复合年增长率为6.8%，到2032 年还将继续成长。预计2019年将达到84亿美元。

脊髓性肌肉萎缩症治疗市场-IMG1

脊髓性肌肉萎缩症 (SMA) 是一种影响运动神经元（控制随意肌肉运动的神经细胞）的遗传性疾病。 其特征是运动神经元进行性退化，导致肌肉无力和萎缩。 SMA 的症状多种多样，但通常包括肌肉无力和萎缩、运动功能受损、呼吸问题和运动能力下降。 症状的严重程度和疾病进展的速度有个别差异。

脊髓性肌肉萎缩症 (SMA) 最广泛使用且有效的治疗方法是基因替代疗法。 其中一种治疗方法称为 Onasemnogene abeparvovec (Zolgensma)。 这涉及使用病毒载体将 SMN1 基因的功能副本（SMA 中缺失）引入运动神经元。 这种治疗在患有 SMA 的婴儿中取得了显着的成功，并可能阻止疾病的进展。

推动全球脊髓性肌肉萎缩症（SMA）治疗市场成长的关键因素是脊髓性肌肉萎缩症（SMA）盛行率的不断增加。 例如，根据美国疾病管制与预防中心(CDC) 2023 年3 月的数据，脊髓性肌肉萎缩症(SMA) 是一种遗传性疾病，大约每10,000 人中就有1 人患有脊髓性肌肉萎缩症。

随着更多病例的诊断和报告，更多的患者需要有效的治疗。 SMA 的日益普及正在促进市场成长的扩大。 Nusinersen 和 Onasemnogene abeparvovec 等疾病缓解疗法的推出彻底改变了 SMA 的治疗格局。 这些治疗改善了 SMA 患者的预后，并提供了显着的临床益处。

目录

第一章简介

第 2 章执行摘要

第三章市场概述

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 脊髓性肌肉萎缩症盛行率不断上升
      • 政府机构的努力
      • 对脊髓性肌肉萎缩症 (SMA) 治疗药物的需求不断增加
    • 抑制因素
      • SMA治疗药物价格高
    • 机会
      • 增加研发活动
  • 新冠肺炎 (COVID-19)：市场影响分析

第 4 章脊髓性肌肉萎缩症 (SMA) 治疗市场：依类型

  • 摘要
  • 类型 1
  • 类型 2
  • 其他

第 5 章脊髓性肌肉萎缩症 (SMA) 治疗市场：依给药途径划分

  • 摘要
  • 口头
  • 注射用

第 6 章脊髓性肌肉萎缩症 (SMA) 治疗市场：依最终使用者划分

  • 摘要
  • 医院
  • 其他

第 7 章脊髓性肌肉萎缩症 (SMA) 治疗市场：按地区

  • 摘要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 拉丁美洲
    • 中东/非洲

第八章竞争态势

  • 简介
  • 关键成功策略
  • 10家主要公司的产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022 年主要公司的定位

第九章公司简介

  • Biogen
  • Cytokinetics
  • Hanugen Theraputics
  • NMD Phrama A/S
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Scholar Rock Holding Corporation
  • Beijing Jinlan Gene Technology Co., Ltd.
  • Ionis Pharmaceuticals, Inc.
Product Code: A107144

According to a new report published by Allied Market Research, titled, "Spinal Muscular Atrophy Treatment Market," The spinal muscular atrophy treatment market was valued at $4.3 billion in 2022, and is estimated to reach $8.4 billion by 2032, growing at a CAGR of 6.8% from 2023 to 2032.

Spinal Muscular Atrophy Treatment Market - IMG1

Spinal muscular atrophy (SMA) is a genetic disorder that affects the motor neurons, which are the nerve cells responsible for controlling voluntary muscle movements. It is characterized by the progressive degeneration of these motor neurons, leading to muscle weakness and atrophy. The symptoms of SMA can vary widely, but they generally involve muscle weakness and atrophy, difficulty with motor function, respiratory problems, and reduced mobility. The severity of the condition and the rate of disease progression can also vary among individuals.

The most widely used and effective treatment for spinal muscular atrophy is gene replacement therapy. One such therapy is called Onasemnogene abeparvovec (Zolgensma). It involves delivering a functional copy of the SMN1 gene (which is deficient in SMA) to motor neurons using a viral vector. This therapy has shown remarkable success in infants with SMA and has the potential to halt disease progression.

The major factors that drive the growth of the global spinal muscular atrophy treatment market include, increase in prevalence of spinal muscular atrophy. For instance, according to the Centers for disease Control and Prevention (CDC) in March 2023, spinal muscular atrophy (SMA) is a genetic disorder that affects approximately 1 out of every 10,000 people.

As more cases are diagnosed and reported, there is a growing patient population that requires effective treatment options. This increase in prevalence of SMA contributes to the expansion of the market growth. The introduction of disease-modifying therapies, such as Nusinersen and Onasemnogene abeparvovec, has revolutionized the treatment landscape for SMA. These therapies have shown significant clinical benefits and improved the prognosis for individuals with SMA, leading to increased demand for SMA drugs and propels the market growth.

In addition, improved understanding, and awareness of SMA among healthcare professionals and the public, there has been an emphasis on early diagnosis through genetic testing. Early detection allows for timely intervention and treatment initiation, which is driving the demand for SMA therapies. Another market driver is the growing recognition of rare diseases significance, rise in initiatives to raise SMA awareness, and increase in research efforts by market participants to develop effective treatments for SMA. However, high cost of the spinal muscular atrophy treatment limits the adoption of SMA drugs which restrain the market growth.

The global spinal muscular atrophy treatment market is segmented into type, route of administration, distribution channel, and region. By type, the market is categorized into type 1, type 2, and others. By route of administration, the market is bifurcated into oral and parenteral. By end user, the market is classified into hospitals and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).

Major key players that operate in the global spinal muscular atrophy treatment market are Biogen, Beijing Jinlan Gene Technology Co., Ltd., Cytokinetics, F. Hoffmann-La Roche Ltd., Hanugen Theraputics, Ionis Pharmaceuticals, Inc. NMD PHARMA A/S, Novartis AG, Pfizer Inc., and Scholar Rock Holding Corporation. Key players operating in the market have adopted product approval, product launch, and agreement as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the spinal muscular atrophy treatment market analysis from 2022 to 2032 to identify the prevailing spinal muscular atrophy treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the spinal muscular atrophy treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global spinal muscular atrophy treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Type 1
  • Type 2
  • Others

By Route of Administration

  • Oral
  • Parenteral

By End User

  • Hospitals
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

Key Market Players:

    • Beijing Jinlan Gene Technology Co., Ltd.
    • Biogen
    • Cytokinetics
    • F. Hoffmann-La Roche Ltd.
    • Hanugen Theraputics
    • Ionis Pharmaceuticals, Inc.
    • NMD Phrama A/S
    • Novartis AG
    • Pfizer Inc.
    • Scholar Rock Holding Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of spinal muscular atrophy
      • 3.4.1.2. Initiatives by government organizations
      • 3.4.1.3. Increase in the demand for drugs for the SMA
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of SMA drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in R&D activities
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Type 1
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Type 2
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oral
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Parenteral
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Others
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Route of Administration
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Type
      • 7.2.5.1.3. Market size and forecast, by Route of Administration
      • 7.2.5.1.4. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Type
      • 7.2.5.2.3. Market size and forecast, by Route of Administration
      • 7.2.5.2.4. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Type
      • 7.2.5.3.3. Market size and forecast, by Route of Administration
      • 7.2.5.3.4. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Route of Administration
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Type
      • 7.3.5.1.3. Market size and forecast, by Route of Administration
      • 7.3.5.1.4. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Type
      • 7.3.5.2.3. Market size and forecast, by Route of Administration
      • 7.3.5.2.4. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Type
      • 7.3.5.3.3. Market size and forecast, by Route of Administration
      • 7.3.5.3.4. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Type
      • 7.3.5.4.3. Market size and forecast, by Route of Administration
      • 7.3.5.4.4. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Type
      • 7.3.5.5.3. Market size and forecast, by Route of Administration
      • 7.3.5.5.4. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Type
      • 7.3.5.6.3. Market size and forecast, by Route of Administration
      • 7.3.5.6.4. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Route of Administration
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Type
      • 7.4.5.1.3. Market size and forecast, by Route of Administration
      • 7.4.5.1.4. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Type
      • 7.4.5.2.3. Market size and forecast, by Route of Administration
      • 7.4.5.2.4. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Type
      • 7.4.5.3.3. Market size and forecast, by Route of Administration
      • 7.4.5.3.4. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Type
      • 7.4.5.4.3. Market size and forecast, by Route of Administration
      • 7.4.5.4.4. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Type
      • 7.4.5.5.3. Market size and forecast, by Route of Administration
      • 7.4.5.5.4. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Type
      • 7.4.5.6.3. Market size and forecast, by Route of Administration
      • 7.4.5.6.4. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Route of Administration
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Latin America
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Type
      • 7.5.5.1.3. Market size and forecast, by Route of Administration
      • 7.5.5.1.4. Market size and forecast, by End User
      • 7.5.5.2. Middle East And Africa
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Type
      • 7.5.5.2.3. Market size and forecast, by Route of Administration
      • 7.5.5.2.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Biogen
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Cytokinetics
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Hanugen Theraputics
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
  • 9.4. NMD Phrama A/S
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Key strategic moves and developments
  • 9.5. Novartis AG
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. F. Hoffmann-La Roche Ltd.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Pfizer Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Scholar Rock Holding Corporation
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Beijing Jinlan Gene Technology Co., Ltd.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Key strategic moves and developments
  • 9.10. Ionis Pharmaceuticals, Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 02. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR TYPE 1, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR TYPE 2, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 06. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 09. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 16. U.S. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 17. U.S. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 18. U.S. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 19. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 20. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 21. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 22. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 25. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 29. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. UK SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 36. UK SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 37. UK SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 38. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 39. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 40. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 44. REST OF EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 45. REST OF EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 47. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 48. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 51. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 52. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 55. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 56. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 58. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 59. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 60. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 61. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 63. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 66. REST OF ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 69. LAMEA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 70. LAMEA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 71. LAMEA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 73. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 74. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 75. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 76. MIDDLE EAST AND AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 77. MIDDLE EAST AND AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 78. MIDDLE EAST AND AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 79. BIOGEN: KEY EXECUTIVES
  • TABLE 80. BIOGEN: COMPANY SNAPSHOT
  • TABLE 81. BIOGEN: PRODUCT SEGMENTS
  • TABLE 82. BIOGEN: PRODUCT PORTFOLIO
  • TABLE 83. CYTOKINETICS: KEY EXECUTIVES
  • TABLE 84. CYTOKINETICS: COMPANY SNAPSHOT
  • TABLE 85. CYTOKINETICS: PRODUCT SEGMENTS
  • TABLE 86. CYTOKINETICS: PRODUCT PORTFOLIO
  • TABLE 87. HANUGEN THERAPUTICS: KEY EXECUTIVES
  • TABLE 88. HANUGEN THERAPUTICS: COMPANY SNAPSHOT
  • TABLE 89. HANUGEN THERAPUTICS: PRODUCT SEGMENTS
  • TABLE 90. HANUGEN THERAPUTICS: PRODUCT PORTFOLIO
  • TABLE 91. NMD PHRAMA A/S: KEY EXECUTIVES
  • TABLE 92. NMD PHRAMA A/S: COMPANY SNAPSHOT
  • TABLE 93. NMD PHRAMA A/S: PRODUCT SEGMENTS
  • TABLE 94. NMD PHRAMA A/S: PRODUCT PORTFOLIO
  • TABLE 95. NMD PHRAMA A/S: KEY STRATERGIES
  • TABLE 96. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 97. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 98. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 99. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 100. NOVARTIS AG: KEY STRATERGIES
  • TABLE 101. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 102. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 103. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 104. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 105. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
  • TABLE 106. PFIZER INC.: KEY EXECUTIVES
  • TABLE 107. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 108. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 109. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 110. SCHOLAR ROCK HOLDING CORPORATION: KEY EXECUTIVES
  • TABLE 111. SCHOLAR ROCK HOLDING CORPORATION: COMPANY SNAPSHOT
  • TABLE 112. SCHOLAR ROCK HOLDING CORPORATION: PRODUCT SEGMENTS
  • TABLE 113. SCHOLAR ROCK HOLDING CORPORATION: PRODUCT PORTFOLIO
  • TABLE 114. SCHOLAR ROCK HOLDING CORPORATION: KEY STRATERGIES
  • TABLE 115. BEIJING JINLAN GENE TECHNOLOGY CO., LTD.: KEY EXECUTIVES
  • TABLE 116. BEIJING JINLAN GENE TECHNOLOGY CO., LTD.: COMPANY SNAPSHOT
  • TABLE 117. BEIJING JINLAN GENE TECHNOLOGY CO., LTD.: PRODUCT SEGMENTS
  • TABLE 118. BEIJING JINLAN GENE TECHNOLOGY CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 119. BEIJING JINLAN GENE TECHNOLOGY CO., LTD.: KEY STRATERGIES
  • TABLE 120. IONIS PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 121. IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 122. IONIS PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 123. IONIS PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 124. IONIS PHARMACEUTICALS, INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN SPINAL MUSCULAR ATROPHY TREATMENT MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE INTENSITY OF RIVALRY
  • FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALSPINAL MUSCULAR ATROPHY TREATMENT MARKET
  • FIGURE 09. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022(%)
  • FIGURE 10. COMPARATIVE SHARE ANALYSIS OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR TYPE 1, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR TYPE 2, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR PARENTERAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. SPINAL MUSCULAR ATROPHY TREATMENT MARKET BY REGION, 2022
  • FIGURE 20. U.S. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 21. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. UK SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. REST OF EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. REST OF ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. MIDDLE EAST AND AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 38. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 39. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 40. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 41. COMPETITIVE DASHBOARD
  • FIGURE 42. COMPETITIVE HEATMAP: SPINAL MUSCULAR ATROPHY TREATMENT MARKET
  • FIGURE 43. TOP PLAYER POSITIONING, 2022
  • FIGURE 44. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 45. BIOGEN: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 46. CYTOKINETICS: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 47. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 49. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 50. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. SCHOLAR ROCK HOLDING CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. IONIS PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)